NCT05134636
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be starting single agent PDL-1/PD-1 targeted immune checkpoint blockade (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab) at Penn’s Abramson Cancer Center
Exclusions: 
https://ClinicalTrials.gov/show/NCT05134636